Alto Neuroscience Inc. (NYSE: ANRO)
$4.5100
+0.0700 ( -1.53% ) 57.8K
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Market Data
Open
$4.5100
Previous close
$4.4400
Volume
57.8K
Market cap
$120.56M
Day range
$4.3520 - $4.6200
52 week range
$3.5600 - $24.0000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Jul 11, 2024 |
| 3 | Insider transactions | 2 | May 22, 2024 |
| 4 | Insider transactions | 1 | May 22, 2024 |
| 8-k | 8K-related | 13 | May 21, 2024 |
| 8-k | 8K-related | 14 | May 14, 2024 |
| 10-q | Quarterly Reports | 65 | May 14, 2024 |
| 4 | Insider transactions | 1 | Apr 01, 2024 |
| 10-k | Annual reports | 37 | Mar 21, 2024 |
| 8-k | 8K-related | 2 | Mar 21, 2024 |
| 4 | Insider transactions | 1 | Mar 12, 2024 |